- News
- Press release
07/12/09
Very positive 3-year results of the long-term study
These results provide confirmation of the clinical relevance of Oralair.
27/11/09
Stallergenes is granted a marketing authorization for Oralair in Europe
Obtention of the European approval in both adults and children through a Mutual Recognition Procedure.
17/11/09
Stallergenes' growth strategy recognized at the "BFM Awards"
Stallergenes picked up the “best stock market performance” prize at the BFM Awards ceremony held on November 16, 2009.
15/10/09
Continued dynamic growth: cumulative sales to the end of september 2009 up 12%
Sales grew at a rate equal to that of the first half year, which was 3 points higher than the growth in the 2nd quarter 2009.
16/09/09
Immunotherapy tablet containing recombinant allergen of birch pollen: positive results for a phase IIb/III trial
First results of a new phase IIb/III clinical trial (VO59.08) conducted in allergic rhinitis caused by birch pollen.
27/08/09
A brand name for the 2nd sublingual desensitization tablet produced by Stallergenes
The tablet for allergic rhinitis caused by exposure to dust mites has been given the following brand name: “ACTAIR”
27/08/09
Webcast - Presentation of 2009 Half-year results
Presentation of 2009 Half-year results to the financial analysts on 27/08/09...
26/08/09
First half-year 2009: performance ahead of expectations
Net profit up 11%, Strong research and investment effort, Positive net financial position, Annual growth guidance maintained at 10%
15/07/09
Strong sales growth in 1st half-year: up 12%, Full-year guidance maintained
2nd quarter growth remained high at 9% (organic 8%), but slowed down compared with the very strong start of the year. Sales growth over the first half-year remained strong at 12% (organic 11%).
29/04/09
House dust mites desensitization tablets: Positive results from a phase IIb/III clinical trial
Release of the first year outcome of the VO 57.07 clinical study on a sublingual house dust mite desensitization tablet.
15/04/09
1st quarter 2009: favourable developments
Continuing strong growth, successful launch of Oralair® in Germany, decrease of the net financial debt
25/03/09
Webcast - Presentation of 2008 results
Presentation of 2008 results to the financial analysts on 25/03/09
24/03/09
2008: a strong performance
Strong growth in results: Sales up 16%, Net profit up 17%,
Sound financial position,
Proposed increase in dividend
24/03/09
Exclusive partnership with Solvay Pharmaceuticals in Russia and the CIS
Signing of an exclusive partnership agreement for the promotion and distribution of Stallergenes diagnostic and treatment products
19/01/09
Oralair® Grasses obtains a pediatric Market Authorisation in Germany
Pediatric extension of the indications for Stallergenes sublingual tablets for desensitization to grass pollens.
19/01/09
Albert Saporta's interview
Interview of Albert Saporta, Chairman & CEO of Stallergenes, dated January 15th, 2009 and directed by Didier Testot for the website www.labourseetlavie.com
27/10/08
Launch of a ph.III clinical trial in adults for Oralair Grasses in the US
Operating income expected to remain stable in 2009
15/10/08
Quarterly information: Continuing growth dynamics
Sales at end September 2008: +17%
2008 sales guidance revised upwards: +14%
07/10/08
Partnership with Catalent and The Medical House
Partnership for commercialization of adrenaline autoinjector in Europe
10/09/08
Stallergenes inaugurates the biggest pharmaceutical allergene production unit in the world
Stallergenes officially inaugurates its new pharmaceutical production unit, located in Paris area.
27/08/08
Oralair® Grasses 300 IR : Highly positive results in a pharmacodynamic study conducted in an allergen challenge chamber
Stallergenes S.A. announces the highly positive results of a new study conducted in an Allergen Challenge Chamber (ACC).
The study on Oralair® Grasses included 86 adult patients exposed to grass pollen challenge with different...
27/08/08
First Half Year 2008: a 19% increase in operating profit and net profit
The Board of Directors, meeting today under the chairmanship of Albert Saporta, approved Stallergenes' half year consolidated financal statements:
10/07/08
Q2 2008 sales up 18%
1st half-year sales up 16%, revision upwards of 2008 sales growth guidance: ≥12%
24/06/08
Obtention of the market authorization in Germany for Oralair® Grasses
Stallergenes has been granted with the market authorization in Germany for its sublingual desensitisation tablet Oralair® Grasses.
12/03/08
2007 results
Further profit growth; Sales up 16%; Profit before R&D up 19%;
Net profit (Group share) up 12%; Acceleration of R&D expenditure
10/01/08
Implementation of a liquidity contract
Stallergenes has entrusted SG Securities Paris with the implementation of a liquidity contract
13/12/07
Partnership for producing mites recombinant allergens
Partnership agreement between Stallergenes and PROTEIN’EXPERT
28/11/07
Oralair® Grasses: Positive results of VO52.06 paediatric study
The results of a study on children confirmed the efficacy of the ORALAIR® Grasses sublingual desensitisation product, which is due to receive German market authorisation shortly.
12/07/07
2007 1st half-year sales up 17%,Q2 sales up 13%
(€ millions) 2007 2006 07/06 % sales % sales % change Southern Europe (1)23.2272.020.5371.813Other EU countries (2)7.6923.86.9124.211Other...
17/04/07
2007 1st quarter sales up 20%
(€ millions) 2007 % of sales 2006 % of sales07/ 06 % Change Southern Europe(1) 33,3278,327,5777,521Other EU countries8,0719,06,8019,119Other markets1,172,71,223,4(4)SLIT34,6381,427,6677,725SCIT6,1714,56,2717,6(2)Other...
15/03/07
Increase in operating profit and additional R&D efforts
The Board of Directors, meeting on 14 March 2007 under the chairmanship of Albert SAPORTA, approved the 2006 consolidated financial statements prepared in accordance with international accounting standards. Comparative 2005...
13/02/07
Stallergenes enters the Netherlands through a joint-venture agreement
Antony,France (Feb. 13, 2007) 'Stallergenes SA today announced that it has set up a joint-venture in the Netherlands in partnership with the Dutch company Sanmed B.V.
The agreement represents an important step forward in...
15/01/07
Strong 13% 2006 full-year growth,2006 4th quarter sales up 13%
€ millions 2006 2005 % increase Quarter 4 sales 37.46 33.14 13% France, including overseas dependencies19.3316.1819%Subsidiaries (1) 14.0913.306%Distributors (2)4.043.6610%Cumulative sales at end December 126.55 112.04 13%...
